» Articles » PMID: 40074426

Comprehensive Evaluation of Antibacterial and Anticancer Activities from Indole Butanoic Acid

Abstract

Focus of this study is on the use of the hydrazone compound (3) (N-(4-bromobenzylidene)-4-(1H-indol-3-yl) butane hydrazide), which was previously prepared from the reaction of the compound p-bromobenzaldehyde with the corresponding hydrazide (2), as an intermediate compound for the synthesis of azetidine, thiazolidine, tetrazole, oxadiazole and phthalazine heterocyclic compounds through its reaction with some cyclic reagents and catalysts such as chloro acetyl chloride, thioglycolic acid, sodium-azid, lead dioxide and Hydrogen chloride gas. The prepared compounds were characterized using physical properties and also spectroscopic methods such as infrared spectroscopy, nuclear magnetic resonance spectra of the proton and the isotope of carbon as well as mass spectrometry, which accurately identified the proposed structures of the prepared compounds. The identity of the prepared compounds was determined using physical and spectroscopic properties, where infrared and HNMR spectroscopy of the proton as well as carbon were used in addition to using mass spectrometry to verify the validity of the prepared structures. Conclusions: Also, the biological antibacterial evaluation of the compounds (4-8) was conducted and it gave a good result compared to the drug (8) used as a reference for the control, The MTT test was performed on the healthy and cancerous cells of the compounds (4,5,8) and gave an excellent result for the compound (8).

References
1.
Martin T, Jiang W . Anti-Cancer agents in medicinal chemistry (Formerly current medicinal chemistry - Anti-cancer agents). Anticancer Agents Med Chem. 2010; 10(1):1. DOI: 10.2174/1871520611009010001. View

2.
Kumari A, Singh R . Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives. Bioorg Chem. 2019; 89:103021. DOI: 10.1016/j.bioorg.2019.103021. View

3.
Bhutani P, Joshi G, Raja N, Bachhav N, Rajanna P, Bhutani H . U.S. FDA Approved Drugs from 2015-June 2020: A Perspective. J Med Chem. 2021; 64(5):2339-2381. DOI: 10.1021/acs.jmedchem.0c01786. View

4.
Cabrele C, Reiser O . The Modern Face of Synthetic Heterocyclic Chemistry. J Org Chem. 2016; 81(21):10109-10125. DOI: 10.1021/acs.joc.6b02034. View

5.
Welsch M, Snyder S, Stockwell B . Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol. 2010; 14(3):347-61. PMC: 2908274. DOI: 10.1016/j.cbpa.2010.02.018. View